Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Brandwein

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|May 3, 2019
A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemiaMohammad Refaei, Osman Radhwi, Irwindeep Sandhu, et al.
Cancer|April 15, 2005
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapyVikas Gupta, Kathy Chun, Qi-Long Yi, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 21, 2019
siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymersJuliana Valencia-Serna, Cezary Kucharski, Min Chen, et al.
Transfusion|December 9, 2004
Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian designAlan Tinmouth, Ian F Tannock, Michael Crump, et al.
Plos One|June 22, 2021
Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)Mahsa Mohseni, Cezary Kucharski, Remant Bahadur K C, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2025
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxJoseph Brandwein, David Page, Elena Liew, et al.
Acta Haematologica|July 19, 2008
Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapyMurtadha Al Khabori, Samira Samiee, Sharon Fung, et al.
International Journal of Molecular Sciences|January 11, 2024
ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid LeukemiaJustine Lai, Claire Yang, Chuquan Shang, et al.
Molecular Therapy. Nucleic Acids|May 13, 2015
Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid LeukemiaBreanne Landry, Juliana Valencia-Serna, Hilal Gul-Uludag, et al.
Acta Biomaterialia|September 5, 2024
Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemiaAysha S Ansari, Cezary Kucharski, Remant Kc, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|May 3, 2019
A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemiaMohammad Refaei, Osman Radhwi, Irwindeep Sandhu, et al.
Cancer|April 15, 2005
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapyVikas Gupta, Kathy Chun, Qi-Long Yi, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 21, 2019
siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymersJuliana Valencia-Serna, Cezary Kucharski, Min Chen, et al.
Transfusion|December 9, 2004
Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian designAlan Tinmouth, Ian F Tannock, Michael Crump, et al.
Plos One|June 22, 2021
Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)Mahsa Mohseni, Cezary Kucharski, Remant Bahadur K C, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2025
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxJoseph Brandwein, David Page, Elena Liew, et al.
Acta Haematologica|July 19, 2008
Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapyMurtadha Al Khabori, Samira Samiee, Sharon Fung, et al.
International Journal of Molecular Sciences|January 11, 2024
ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid LeukemiaJustine Lai, Claire Yang, Chuquan Shang, et al.
Molecular Therapy. Nucleic Acids|May 13, 2015
Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid LeukemiaBreanne Landry, Juliana Valencia-Serna, Hilal Gul-Uludag, et al.
Acta Biomaterialia|September 5, 2024
Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemiaAysha S Ansari, Cezary Kucharski, Remant Kc, et al.
Pageof 8